COVID-19

Larimar Therapeutics remains firmly committed to the study of CTI-1601 in people with Friedreich’s Ataxia. In view of the recent circumstances concerning COVID-19, our Phase 1 study, CTI-1601, has been temporarily paused. We were able to collect the necessary data up to the time of the pause, but additional data will need to be collected to complete the study.

We are monitoring the recommendations coming from health authorities and will continue to study CTI-1601 in this and future studies as soon as the situation with COVID-19 permits.